Fulcrum Therapeutics presented Phase 2 data at ASH 2023 showing pociredir increased fetal hemoglobin by 8.2% in sickle cell patients,…
Recent AI screening data reveals health inequities in diabetic eye care
This article analyzes how algorithmic bias in AI medical screening perpetuates health disparities, drawing on clinical evidence from diabetic retinopathy…
Memorial Sloan Kettering’s AI clinical trial data shows improved patient matching and operational efficiency
Memorial Sloan Kettering’s AI system achieved 100% accuracy in patient matching for clinical trials, identifying all manually screened candidates and…
Paradromics’ FDA IDE approval reveals accelerated neurotech regulatory pathways
The FDA’s approval of Paradromics’ BCI clinical trial for speech restoration in paralyzed patients highlights advancements in neurotechnology. This analysis…
What FDA and WHO vaccine regulatory updates mean for public health outcomes
This article examines recent FDA and WHO proposals to update vaccine ingredients and schedules, based on clinical evidence from studies…
What FDA’s CRISPR approvals mean for rare disease economics
The FDA’s 2023 approval of CRISPR therapies for sickle cell disease and beta-thalassemia highlights clinical benefits like reduced crises and…
Arcascience secures €6M to combat pharmaceutical R&D failures with AI-driven benefit-risk assessment
ArcaScience’s €6M funding round accelerates AI-powered drug development, targeting the industry’s 90% failure rate by analyzing 100B+ health data points.…
Seluna’s NHS-backed AI trial aims to solve pediatric sleep disorder crisis
Seluna launches NHS-partnered clinical trial for explainable AI diagnosing children’s sleep disorders, addressing 80% underdiagnosis rate with planned 2026 UK…
AI reshapes pharmaceutical valuations as drug discovery platforms demonstrate clinical success
Recent Phase II successes and multi-billion dollar partnerships are validating AI-driven drug discovery, forcing investors to reconsider traditional pharma valuation…
European startups harness AI to reshape clinical trials and patient monitoring
Biorce and Cumulus Neuroscience lead AI-driven healthcare transformation in Europe, reducing clinical trial delays by 50% and enabling real-time neurological…
Novel AI Approach Enhances Drug Safety with 97% Precision in Interaction Predictions
A new GCN-based AI method eliminates negative sampling in drug-drug interaction prediction, achieving 97% precision. This innovation addresses pharmaceutical data…
Asia’s Rapid-Cycle AI Deployment Models Accelerate Blindness Treatment Innovations
Recent clinical validations demonstrate robust AI diagnostic capabilities while Asia’s agile implementation frameworks create scalable pathways for vision-preserving technologies. Emerging…